Purple Biotech completes patient enrollment in Phase 2 pancreatic cancer trial

Purple Biotech (PPBT) has completed patient enrollment in a Phase 2 study of CM24, a multi-functional immune checkpoint inhibitor, for the treatment of pancreatic ductal adenocarcinoma – PDAC -. The Phase 2 study, in collaboration with Bristol Myers Squibb (BMY), is evaluating CM24 in combination with BMS’s nivolumab plus chemotherapy in PDAC patients as a 2nd line treatment as compared to chemotherapy alone. The primary endpoint is overall survival. Approximately 60 patients have been enrolled. The trial was fully enrolled in advance of the anticipated 2024 timeline. An interim analysis of overall survival, the primary endpoint of the study is expected during 1H 2024 and topline analysis is expected in 2H 2024.